Vaccine-induced seropositivity

Last updated

Vaccine-induced seropositivity (VISP) is the phenomenon wherein a person who has received a vaccine against a disease would thereafter give a positive or reactive test result for having that disease when tested for it, despite not actually having the disease. This happens because many vaccines encourage the body to produce antibodies against a particular disease, and blood tests often determine whether a person has those antibodies, regardless of whether they came from the infection or just a vaccination. Vaccines of COVID-19 also cause this phenomenon, which has caused the severe reaction to the vaccines in humans. [1]

Contents

VISP is especially a concern in vaccine trials for HIV vaccine research because people who give a positive result in an HIV test, even if that result is because of a vaccine and not because of an infection, may face discrimination because of HIV infection.

HIV

Background

In 1987 in America the first HIV vaccine was tested. [2] HIV vaccines have been tested continually worldwide since then, but thus far, no one has developed any vaccine which reduces a person's risk of contracting HIV if exposed to that virus.[ citation needed ]

Many HIV tests work not by checking a person's blood for HIV, but rather by determining whether the body's own antibodies against HIV are present in the blood.[ citation needed ] Most HIV vaccines are designed with the intent to promote the body's own production of antibodies which would combat HIV.[ citation needed ] Regardless of whether they are effective at stimulating the production of antibodies which fight HIV, they usually do cause the body to produce antibodies which standard HIV tests recognize as the antibodies which an HIV positive person would produce in response to HIV infection.[ citation needed ]

A person who is HIV negative, and has received an HIV vaccine, and who then tests as positive in an HIV test is said to be positive because of VISP.[ citation needed ]

Significance

When an HIV-negative person exhibits VISP and gets an HIV-positive result from a test then that person may have difficulty donating blood or negotiating for a life insurance policy. [3]

Between 1987 and 2003 the number of persons who received experimental HIV vaccinations was about 10,000, and this number was considered small. The difficulties in determining the difference between antibodies produced by HIV infection and vaccine-induced antibodies were managed by individual vaccine research sites who had special capability to conduct additional laboratory testing on this small pool of vaccine recipients. However, at this time two new studies, the STEP Study in the US and the RV 144 study in Thailand, greatly increased the number of people who received HIV vaccinations by another 4600 people. [4] There came to be an increased need to raise awareness of VISP because more people were exhibiting it.[ citation needed ]

At the 2010 International AIDS conference presenters talked about the need for community healthcare providers to understand that if their patients have been in an HIV vaccine trial then their patients are likely to give a false positive HIV test result. [5]

HIV VISP in developing countries

HIV vaccine research happens worldwide to ensure that any vaccine which researchers develop could be used for people worldwide. In developing countries with limited access to healthcare, the problems associated with VISP are a special concern.[ citation needed ]

Researchers from Africa, Asia, North America, and South America have said that getting local government and media support of the research is essential in addition to creating facilities for distinguishing between HIV positive individuals and individuals exhibiting VISP. [6]

Likelihood

People who participate in vaccine trials which test HIV vaccines may exhibit VISP for years or for the rest of their lives.[ citation needed ]

A study done on participants in the HIV Vaccine Trials Network HIV vaccination studies showed that among 2176 HIV negative participants who received a vaccine, 908 (42%) had VISP. However, the occurrence of VISP varied depending on what kind of vaccine the participants received. [7]

Hepatitis B

When a person gets a hepatitis B vaccine then the most common test for hepatitis B will show them to be positive. The usual course of action, in this case, is to give the person a panel of tests for HBsAg, anti-HBc, and anti-HBs (hepatitis B surface antigen, anti-hepatitis B core, and anti-hepatitis B surface). A person who has never been exposed to hepatitis B but has gotten the vaccine will be positive for anti-HBs but negative for the other two tests in the panel. Other combinations of positive and negative in this test can mean other things, such as acute, chronic, or past infection. [8]

Other conditions

VISP is not often a practical concern for other diseases because in most cases good vaccines already exist and most people who have access to healthcare receive them. Also physicians do not routinely test people for recent infections with most diseases as they do for HIV.Medical literature on VISP for most diseases is not widely available because there is little practical need for doing that research.[ citation needed ]

Related Research Articles

Hepatitis An inflammation of the liver.

Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months. Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.

DNA vaccine Vaccine containing DNA

A DNA vaccine is a type of vaccine that transfects a specific antigen-coding DNA sequence onto the cells of an immunized species.

Antiviral drugs are a class of medication used for treating viral infections. Most antivirals target specific viruses, while a broad-spectrum antiviral is effective against a wide range of viruses. Unlike most antibiotics, antiviral drugs do not destroy their target pathogen; instead they inhibit its development.

Mantoux test Immunological method to test for tuberculosis

The Mantoux test or Mendel–Mantoux test is a tool for screening for tuberculosis (TB) and for tuberculosis diagnosis. It is one of the major tuberculin skin tests used around the world, largely replacing multiple-puncture tests such as the tine test. The Heaf test, a form of tine test, was used until 2005 in the UK, when it was replaced by the Mantoux test. The Mantoux test is endorsed by the American Thoracic Society and Centers for Disease Control and Prevention. It was also used in the USSR and is now prevalent in most of the post-Soviet states.

Q fever Disease caused by infection with Coxiella burnetii

Q fever or query fever is a disease caused by infection with Coxiella burnetii, a bacterium that affects humans and other animals. This organism is uncommon, but may be found in cattle, sheep, goats, and other domestic mammals, including cats and dogs. The infection results from inhalation of a spore-like small-cell variant, and from contact with the milk, urine, feces, vaginal mucus, or semen of infected animals. Rarely, the disease is tick-borne. The incubation period is 9–40 days. Humans are vulnerable to Q fever, and infection can result from even a few organisms. The bacterium is an obligate intracellular pathogenic parasite.

HIV vaccine development In-progress vaccinations that may prevent or treat HIV infections

An HIV vaccine could be either a preventive vaccine or a therapeutic vaccine, which means it will either protect individuals from being infected with HIV or treat HIV-infected individuals. And it could either induce an immune response against HIV or consist of preformed antibodies against HIV.

Diagnosis of HIV/AIDS

HIV tests are used to detect the presence of the human immunodeficiency virus (HIV), the virus that causes acquired immunodeficiency syndrome (AIDS), in serum, saliva, or urine. Such tests may detect antibodies, antigens, or RNA.

Hepatitis A Acute infectious disease of the liver


Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral hepatitis. Many cases have few or no symptoms, especially in the young. The time between infection and symptoms, in those who develop them, is 2-6 weeks. When symptoms occur, they typically last 8 weeks and may include nausea, vomiting, diarrhea, jaundice, fever, and abdominal pain. Around 10–15% of people experience a recurrence of symptoms during the 6 months after the initial infection. Acute liver failure may rarely occur, with this being more common in the elderly.

The spread of HIV/AIDS has affected millions of people worldwide; AIDS is considered a pandemic. The World Health Organization (WHO) estimated that in 2016 there were 36.7 million people worldwide living with HIV/AIDS, with 1.8 million new HIV infections per year and 1 million deaths due to AIDS. Misconceptions about HIV and AIDS arise from several different sources, from simple ignorance and misunderstandings about scientific knowledge regarding HIV infections and the cause of AIDS to misinformation propagated by individuals and groups with ideological stances that deny a causative relationship between HIV infection and the development of AIDS. Below is a list and explanations of some common misconceptions and their rebuttals.

Post-exposure prophylaxis, also known as post-exposure prevention (PEP), is any preventive medical treatment started after exposure to a pathogen in order to prevent the infection from occurring.

The Jade Ribbon Campaign (JRC) also known as JoinJade, was launched by the Asian Liver Center (ALC) at Stanford University in May 2001 during Asian Pacific American Heritage Month to help spread awareness internationally about hepatitis B (HBV) and liver cancer in Asian and Pacific Islander (API) communities.

Serosorting, also known as serodiscrimination is the practice of using HIV status as a decision-making point in choosing sexual behavior. Frequently the term is used to describe the behavior of a person who chooses a sexual partner assumed to be of the same HIV serostatus in order to engage in unprotected sex with them for a reduced risk of acquiring or transmitting HIV/AIDS.

In medicine, the window period for a test designed to detect a specific disease is the time between first infection and when the test can reliably detect that infection. In antibody-based testing, the window period is dependent on the time taken for seroconversion.

Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) co-infection is a multi-faceted, chronic condition that significantly impacts public health. According to the World Health Organization (WHO), 2 to 15% of those infected with HIV are also affected by HCV, increasing their risk of morbidity and mortality due to accelerated liver disease. The burden of co-infection is especially high in certain high-risk groups, such as intravenous drug users and men who have sex with men. These individuals who are HIV-positive are commonly co-infected with HCV due to shared routes of transmission including, but not limited to, exposure to HIV-positive blood, sexual intercourse, and passage of the Hepatitis C virus from mother to infant during childbirth.

HBsAg Surface antigen of the hepatitis B virus

HBsAg is the surface antigen of the hepatitis B virus (HBV). It indicates current hepatitis B infection.

<i>Human betaherpesvirus 5</i> Species of virus

Human betaherpesvirus 5, also called human cytomegalovirus (HCMV), is species of virus in the genus Cytomegalovirus, which in turn is a member of the viral family known as Herpesviridae or herpesviruses. It is also commonly called CMV. Within Herpesviridae, HCMV belongs to the Betaherpesvirinae subfamily, which also includes cytomegaloviruses from other mammals. CMV is a double-stranded DNA virus.

Hepatitis B vaccine Vaccine against hepatitis B

Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.

Hepatitis B Human viral infection

Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver; it is a type of viral hepatitis. It can cause both acute and chronic infection. Many people have no symptoms during the initial infection. In acute infection, some may develop a rapid onset of sickness with vomiting, yellowish skin, tiredness, dark urine, and abdominal pain. Often these symptoms last a few weeks and rarely does the initial infection result in death. It may take 30 to 180 days for symptoms to begin. In those who get infected around the time of birth 90% develop chronic hepatitis B while less than 10% of those infected after the age of five do. Most of those with chronic disease have no symptoms; however, cirrhosis and liver cancer may eventually develop. Cirrhosis or liver cancer occur in about 25% of those with chronic disease.

HVTN 505 is a clinical trial testing an HIV vaccine regimen on research participants. The trial is conducted by the HIV Vaccine Trials Network and sponsored by the National Institute of Allergy and Infectious Diseases. Vaccinations were stopped in April 2013 due to initial results showing that the vaccine was ineffective in preventing HIV infections and lowering viral load among those participants who had become infected with HIV. All study participants will continue to be monitored for safety and any long-term effects.

Intrastructural help (ISH) is where T and B cells cooperate to help or suppress an immune response gene. ISH has proven effective for the treatment of influenza, rabies related lyssavirus, hepatitis B, and the HIV virus. This process was used in 1979 to observe that T cells specific to the influenza virus could promote the stimulation of hemagglutinin specific B cells and elicit an effective humoral immune response. It was later applied to the lyssavirus and was shown to protect raccoons from lethal challenge. The ISH principle is especially beneficial because relatively invariable structural antigens can be used for the priming of T-cells to induce humoral immune response against variable surface antigens. Thus, the approach has also transferred well for the treatment of hepatitis B and HIV.

References

  1. ↑ Samarakoon, Upeka; Alvarez-Arango, Santiago; Blumenthal, Kimberly G. (9 June 2021). "Delayed Large Local Reactions to mRNA Covid-19 Vaccines in Blacks, Indigenous Persons, and People of Color". New England Journal of Medicine. 0 (0): null. doi:10.1056/NEJMc2108620. ISSN   0028-4793.
  2. ↑ "Clinical Trials of HIV Vaccines". National Institute of Allergy and Infectious Diseases. Retrieved 7 February 2014.
  3. ↑ Van Braeckel, E.; Koutsoukos, M.; Bourguignon, P.; Clement, F. D. R.; McNally, L.; Leroux-Roels, G. (2011). "Vaccine-induced HIV seropositivity: A problem on the rise". Journal of Clinical Virology. 50 (4): 334–337. doi:10.1016/j.jcv.2011.01.003. PMID   21300566.
  4. ↑ Ackers, Marta-Louise; Parekh, Bharat; Evans, Thomas G.; Berman, Phillip; Phillips, Susan; Allen, Mary (2003). "Human Immunodeficiency Virus (HIV) Seropositivity among Uninfected HIV Vaccine Recipients". The Journal of Infectious Diseases . University of Chicago Press. 187 (6): 879–886. doi: 10.1086/368169 . PMID   12660933 . Retrieved 29 June 2011.
  5. ↑ Keller, Daniel M. (20 July 2010). "Antibodies Induced by HIV Vaccines May Give False-Positive HIV Test Results". medscape.com. Medscape . Retrieved 28 June 2011.
  6. ↑ Lurie, P.; Bishaw, M.; Chesney, M. A.; Cooke, M.; Fernandes, M. E.; Hearst, N.; Katongole-Mbidde, E.; Koetsawang, S.; Lindan, C. P.; Mandel, J. (1994). "Ethical, behavioral, and social aspects of HIV vaccine trials in developing countries". JAMA: The Journal of the American Medical Association. 271 (4): 295–301. doi:10.1001/jama.271.4.295. PMID   8295289.
  7. ↑ Cooper, CJ; Metch, B; Dragavon, J; Coombs, RW; Baden, LR (21 July 2010). "Vaccine-induced HIV seropositivity/reactivity in noninfected HIV vaccine recipients". Journal of the American Medical Association . American Medical Association. 304 (3): 275–83. doi:10.1001/jama.2010.926. PMC   3086635 . PMID   20639561.
  8. ↑ "WHO | Hepatitis B". who.int. World Health Organization. 2011. Retrieved 7 July 2011. See the table "HBV serological markers in hepatitis patients"
  • Surender Khurana, Needham J, Mathieson B, Rodriguez-Chavez IR, Catanzaro AT, Bailer RT, Kim J, Polonis V, Cooper DA, Guerin J, Peterson ML, Gurwith M, Nguyen N, Graham BS, Golding H. Human Immunodeficiency Virus (HIV) Vaccine Trials: a Novel Assay for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies. J. Virol. (2006); 80(5): 2092–99./>
  • Surender Khurana, Needham J, Park S, Mathieson B, Busch MP, Nemo G, Nyambi P, Zolla-Pazner S, Laal S, Mulenga J, Chomba E, Hunter E, Allen S, McIntyre J, Hewlett I, Lee S, Tang S, Cowan E, Beyrer C, Altfeld M, Yu XG, Tounkara A, Koita O, Kamali A, Nguyen N, Graham BS, Todd D, Mugenyi P, Anzala O, Sanders E, Ketter N, Fast P, Golding H. HIV-SELECTEST, A Novel approach for differential diagnosis of HIV infections in the face of vaccine generated antibodies: Utility for detection of diverse HIV-1 subtype. JAIDS (2006); 43(3): 304–12./>
  • Surender Khurana, Norris PJ, Busch MP, Haynes BF, Park S, Sasono P, Mlisana K, Salim AK, Hecht FM, Mulenga J, Chomba E, Hunter E, Allen S, Nemo G, Rodriguez-Chavez IR; Women's Interagency HIV Study Collaborative Study Group, Margolick JB; Multicenter AIDS Cohort Study (MACS), Golding H. HIV-SELECTEST EIA and Rapid Test: Utility for detection of seroconversion following acute HIV-1 infections. J. Clin. Microb. (2010); 48(1):281-85./>
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.